摘要：SummaryAmyotrophic lateral sclerosis (ALS) is a degenerative disease that progressively destroys motor neurons (MNs). Earlier studies identified EphA4, a receptor tyrosine kinase, as a possible disease-modifying gene. The complex interplay between the EphA4 receptor and its ephrin ligands in motor neurons and astrocytes has not yet been fully elucidated and includes a putative pro-apoptotic activity of the unbound receptor compared to ephrin-bound receptor. We recently reported that astrocytes from patients with ALS induce cell death in co-cultured MNs. Here we found that first-generation synthetic EphA4 agonistic agent 123C4, effectively protected MNs when co-cultured with reactive astrocytes from patients with ALS from multiple subgroups (sALS and mutant SOD1). Newer generation and more potent EphA4 agonistic agents 150D4, 150E8, and 150E7 provided effective protection at a lower therapeutic dose. Combined, the data suggest that the development of EphA4 agonistic agents provides potentially a promising therapeutic strategy for patients with ALS.Graphical abstractDisplay OmittedHighlights•We report on potent and selective EphA4 agents targeting its ligand-binding domain•We used a method that generates neuronal progenitor cells from patient fibroblasts•The agents reverse motor neuron cell death are cellular models of patients with ALS•Our EphA4 agonists can effectively prevent astrocyte-mediated motor neuron toxicityMedical biochemistry; Molecular biology; Neuroscience
